
متى سيتم صرف الادوية بهذه الطريقة ؟؟؟ وهل تعتقدون ان هذه الطريقة ستنجح لدينا في الدول العربية ؟؟؟ ثم ما هو مصير الصيدلاني ؟؟؟…
Shire said on Tuesday it submitted a marketing application to US regulators for its
enzyme replacement therapy for Fabry disease, Replagal (agalsidase alfa).
The treatment is currently available in the country through an FDA-approved programme to address an ongoing shortage of the only approved therapy for Fabry disease, Genzyme's Fabrazyme (agalsidase beta).

|
Joomlastyle.net web hosting & design services |